# Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

> **NCT05358249** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 74 (actual)

## Conditions studied

- KRAS G12C Mutant Solid Tumors
- Carcinoma, Non-Small Cell Lung
- Carcinoma, Non-Small-Cell Lung
- Non-Small Cell Lung Cancer
- Non-Small Cell Lung Carcinoma
- Nonsmall Cell Lung Cancer
- Colorectal Cancer
- Colorectal Carcinoma
- Colorectal Neoplasms
- Colorectal Tumors
- Neoplasms, Colorectal

## Interventions

- **DRUG:** JDQ443
- **DRUG:** trametinib
- **DRUG:** Ribociclib
- **BIOLOGICAL:** cetuximab

## Key facts

- **NCT ID:** NCT05358249
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-10-24
- **Primary completion:** 2026-07-29
- **Final completion:** 2026-07-30
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05358249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05358249, "Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT05358249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*